Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

Abstract Introduction: Immune surveillance, distribution, interactions, and antigen presentation within the tumor microenvironment (TME) may influence anti-tumor reactivity survival. Methods: Dichotomized newly diagnosed treatment-naïve IDH1 wild-type glioblastoma, negative MGMT promotor methylation (65%), short-term (STS; ≤ 6 months; mean age 66 years; n=10) or long-term (LTS; >2 50 survivors, were profiled using high dimensional fluorescence multiplex staining spatial analysis of TME a panel 26 markers. Results: The amounts specific immune cells (CD4 +, CD8 FOXP3 CD11c CD20 CD68 CD205 NKG2D +) similar between cohorts, except STS enriched with CD163 +expressing macrophages LTS had more P2RY12 +microglia throughout TME. There was minimal MHC-I expression no difference in MHC-II on myeloid populations (CD68 and/or combination) both cohorts. TIM-3 only regulator substantially expressed other populations, irrespective Perivascular clustering +CD163 +cells cases. cases demonstrated adaptive activation processes, including +P2RY12 +CD205 interacting CD45RO −naïve, non-exhausted (PD-1 −, LAG3 Tim3 −) +T expressing LCK +immune synaptic marker. Conclusion: interactions CD8+ T microglia help determine versus GBM patients.